Sage Therapeutics’ (SAGE) “Hold” Rating Reaffirmed at Chardan Capital
Other equities analysts also recently issued reports about the company. BidaskClub downgraded Sage Therapeutics from a strong-buy rating to a buy rating in a research report on Monday, July 31st. BMO Capital Markets reaffirmed a buy rating and issued a $82.00 price target on shares of Sage Therapeutics in a report on Friday, July 28th. Stifel Nicolaus reaffirmed a buy rating and issued a $90.00 price target on shares of Sage Therapeutics in a report on Friday, July 14th. Canaccord Genuity set a $110.00 price target on Sage Therapeutics and gave the company a buy rating in a report on Saturday, August 5th. Finally, Cowen and Company reaffirmed a buy rating and issued a $100.00 price target on shares of Sage Therapeutics in a report on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $84.25.
Sage Therapeutics (SAGE) traded down 8.81% during mid-day trading on Wednesday, reaching $64.17. The company’s stock had a trading volume of 1,104,868 shares. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80. The firm’s market capitalization is $2.40 billion. The stock’s 50-day moving average is $82.79 and its 200-day moving average is $74.97.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by ($0.25). During the same period last year, the business posted ($1.08) earnings per share. On average, equities analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Sage Therapeutics’ (SAGE) “Hold” Rating Reaffirmed at Chardan Capital” was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/sage-therapeutics-sage-hold-rating-reaffirmed-at-chardan-capital.html.
A number of institutional investors have recently modified their holdings of the business. Teachers Advisors LLC grew its stake in shares of Sage Therapeutics by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 49,296 shares of the biopharmaceutical company’s stock valued at $2,517,000 after purchasing an additional 6,419 shares during the last quarter. Bank of Montreal Can boosted its stake in Sage Therapeutics by 7,004.1% in the first quarter. Bank of Montreal Can now owns 12,006 shares of the biopharmaceutical company’s stock valued at $853,000 after acquiring an additional 11,837 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Sage Therapeutics in the first quarter valued at approximately $256,000. Russell Investments Group Ltd. boosted its stake in Sage Therapeutics by 82.1% in the first quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 8,872 shares during the last quarter. Finally, Swiss National Bank boosted its stake in Sage Therapeutics by 3.2% in the first quarter. Swiss National Bank now owns 52,100 shares of the biopharmaceutical company’s stock valued at $3,703,000 after acquiring an additional 1,600 shares during the last quarter.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.